Cadence Pharmaceuticals Initiates Pivotal Phase III Clinical Trial Evaluating Intravenous Acetaminophen For Post-Operative Acute Pain

... Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced it has begun dosing subjects in a Phase III clinical trial to evaluate intravenous acetaminophen (IV APAP) for the treatment of post-operative acute pain. [click link for full article] ...